Tumor-induced host immunosuppression: Special focus on CLL

International Immunopharmacology

Volumn 17, Issue 1, 2013, Pages 35-41

  Cutucache, Christine E ^a  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Chronic lymphocytic leukemia; Immune effector cells; Immune surveillance; Suppressor cells; Tumor induced immunosuppression

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; COLONY STIMULATING FACTOR 1; HLA G ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; LENALIDOMIDE; PLECKSTRIN; RITUXIMAB; SYNTROPHIN; TRANSFORMING GROWTH FACTOR BETA; UTROPHIN; VASCULOTROPIN;

ANTIGEN PRESENTATION; ARTICLE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE; FOLLICULAR LYMPHOMA; HOST RESISTANCE; HUMAN; IMMUNE EVASION; IMMUNOLOGICAL TOLERANCE; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR INDUCED HOST IMMUNOSUPPRESSION; TUMOR MICROENVIRONMENT;

EID: 84879041234     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.05.021     Document Type: Review

References (94)

1. Smoley SA, Van Dyke DL, Kay NE, Heerema NA. Dellaquila ML, Dal Cin P, et al. Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet 2010;203:141-8.
2. Caligaris-Cappio F, Ghia P. The nature and origin of the B-chronic lymphocytic leukemia cell: a tentative model. Hematol Oncol Clin North Am 2004;18:849-62. (Pubitemid 39119828)
3. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2011;117: 1781-91.
4. Stevenson FK, Krvsov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011;118:4313-20.
5. Garcia-Munoa R, Galiacho VR, Llorente L. Immunological aspects in chronic lymphocytic leukemia (CLL) development. Ann Hematol 2012;91:981-96.
6. Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Durig J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 2012;209: 2183-98.
7. O'Garra A, Howard M. IL-10 production by CD5 B cells. Ann N Y Acad Sci 1992;651: 182-99.
8. Yen Chong S, Lin YC, Czarneski J, Zhang M, Coffman F, Kashanchi F, et al. Cell cycle effects of IL-10 on malignant B-1 cells. Genes Immun 2001;2:239-47. (Pubitemid 33681705)
9. Di Lillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann NY Acad Sci 2010;1183:38-57.
10. Nordgren TM, Joshi SS. The etiology of chronic lymphocytic leukemia: another look at the relationship between B1 cells and CLL. Open Leuk J 2010;3:69-73.
11. Di Lillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y, et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia 2013;27:170-82.
12. Linet MS, Schubauer-Berigan MK, Weisenburger DD, Richardson DB, Landgren O, Blair A, et al. Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. Br J Haematol 2007;139: 672-86. (Pubitemid 350115718)
13. Vu UE, Pavletic ZS, Wang X, Joshi SS. Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: potentials for therapeutic use. Leuk Lymphoma 2000;39:573-82. (Pubitemid 32162395)
14. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma 2002;43: 461-6. (Pubitemid 34232911)
15. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victra GD, et al. TGF-beta-induced Foxp3 inhibits T[H]17 cell differentiation by antagonizing RORgamma function. Nature 2008;453:236-40. (Pubitemid 351667978)
16. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118: 2427-37. (Pubitemid 351949771)
17. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 2010;116: 4532-41.
18. Weiss L, Melchardt T, Egle A, Grabmer C, Greil R, Tinhofer I. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 2011;117:2163-9.
19. Audrito V, Vaisitti T, Serra S, Bolgna C, Brusa D, Malavasi F, et al. Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. Cancer Lett 2013;328:27-35.
20. Plander M, Seegers S, Ugocsai P, Diermeier-Daucher S, Ivanyl J, Schmitz G, et al. Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukaemia 2009;23:2118-28.
21. Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009;113:3050-8.
22. Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, Marconi D, et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009;69:4001-9.
23. Deaglio S, Vaisitti T, Aydin S, Bergui L, D'Arena G, Bonello L, et al. CD38 and ZAP70 are functionally linked and mark CLL cells with high migratory potential. Blood 2007;110:4012-21. (Pubitemid 350248457)
24. Buchner M, Brantner P, Stickel N, Prinz G, Burger M, Bar C, et al. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia-CXCR4 antagonists as potential adjuvants for monoclonal antibodies. Br J Haematol 2010;151:167-78.
25. Porakishvili N, Kardava L, Jewell AP, Yong K, Glennie MJ, Akbar A, et al. Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica 2004;89:435-43. (Pubitemid 38798548)
26. Katz DH, Benacerraf B. The regulatory influence of activated T cells on B cell responses to antigen. Adv Immunol 1972;15:1-94.
27. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells. Adv Exp Med Biol 2007;601:213-23.
28. Scrivener S, Goddard RV, Kaminski ER, Prentice AG. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44:383-9. (Pubitemid 36118829)
29. Grzywnowicz M, Zaleska J, Mertens D, Tomczak W, Wlasiuk P, Kosior K, et al. Programmed death-1 and its ligand are novel immunotolerantmolecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One 2012;7:e35178.
30. Tonino SH, van de Berg PJ, Yong SL, ten Berge IJ, Kersten MJ, van Lier RA, et al. Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:1785-94.
31. Xerri L, Chetaille B, Serriari N, Attias C, Guillaume Y, Arnoulet C, et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol 2008;39:1050-8.
32. Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C. Expansion of CD8(+) PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer Res 2012;18: 678-87.
33. Muenst S, Hoeller S, Willi N, Dirnhofera S, Tzankov A. Diagnostic and prognostic utility of PD-1 in B cell lymphomas. Dis Markers 2010;29:47-53.
34. Jak M, Mous R, Remmerswaal EB, Spijker R, Jaspers A, Yague A, et al. Enhanced formation and survival of CD4 + CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:788-801.
35. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, et al. Reduced frequencies and suppressive function of CD4 + CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106: 2018-25. (Pubitemid 41291715)
36. Hus I, Schmitt M, Tabarkiewicz J, Radej S, Wojas K, Bojarska-Junak A, et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4 + CD25 + FOXP3+ regulatory T cells toward an antileukemia response. Leukemia 2008;22:1007-17. (Pubitemid 351689883)
37. Giannopoulos K, Schmitt M, Kowal M, Wlasiuk P, Bojarska-Junak A, Chen J, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008;20:677-82.
38. Deutsch V, Perry C, Polliack A. Expansion of regulatory T cells in B chronic lymphocytic leukemia: enhanced 'brakes' on host immunity. Leuk Lymphoma 2009;50: 687-8.
39. Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumorinduced immune suppression. Cancer Metastasis Rev 2011;30:125.
40. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002;99: 1030-7. (Pubitemid 34525568)
41. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, et al. Small peptide inhibitors of the CXCR4 chemokine receptor [CD184] antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005;106:1824-30. (Pubitemid 41208600)
42. Ysebaert L, Fournie JJ. Genomic and phenotypic characterization of nurse-like cells that promote drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 2011;52:1404-6.
43. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-63.
44. Bhattacharya N, Diener S, Idler IS, Rauen J, Habe S, Busch H, et al. Nurse-like cells show deregulated expression of genes involved in immunoincompetence. Br J Haematol 2011;154:349-56.
45. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol 2006;176:705-10. (Pubitemid 43099663)
46. Engel P, Gomez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011;63: 127-56.
47. Gupta S, Agrawal S, Gollapudi S. Increased activation and cytokine secretion in B cells stimulated with leptin in aged humans. Immun Ageing 2013;10:3.
48. Gilling CE, Mittal AK, Chaturvedi NK, Iqbal J, Aoun P, Bierman PJ, et al. Lymph node-induced immune tolerance in chronic lymphocytic leukemia: a role for caveolin-1. Br J Haematol 2012;158:216-31.
49. Tomassian T, Humphries LA, Liu SD, Silva O, Brooks DG, Miceli MC. Caveolin-1 orchestrates TCR synaptic polarity, signal specificity, and function in CD8 T cells. J Immunol 2011;187:2993-3002.
50. Scielzo C, Bertilaccio MT, Simonetti G, Dagklis A, Ten Hacken E, Fazi C, et al. HS1 has a central role in the trafficking and homing of leukemic B cells. Blood 2010;116: 3537-46.
51. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, et al. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009;113:5549-57.
52. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukaemia 2012;26:1576-83.
53. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al. The Bruton tyrosine kinase inhibitor PCR-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012;119:1182-9.
54. Stratowa C, Loffler G, Lichter P, Stilgenbauer S, Haberl P, Schweifer N, et al. CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Cancer 2001;91:474-80. (Pubitemid 32115100)
55. Mateo V, Brown EJ, Biron G, Rubio M, Fischer A, Deist FL, et al. Mechanisms of CD47-induced caspase-independent cell death in normal and leukemic cells: link between phosphatidylserine exposure and cytoskeleton organization. Blood 2002;100:2882-90.
56. Kienle D, Benner A, Krober A, Winkler D, Mertens D, Buhler A, et al. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood 2006;107:2090-3. (Pubitemid 43289393)
57. Liu FT, Giustiniani J, Farren T, Jia L, Bensussan A, Gribben JG, et al. CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. Blood 2010;115:3079-88.
58. Burger JA, Hoellenriegel J. Phosphoinositide 3'-kinase delta: turning off BCR signaling in chronic lymphocytic leukemia. Oncotarget 2011;2:737-8.
59. Costantini JL, Cheung SM, Hou S, Li H, Kung SK, Johnston JB, et al. TAPP2 links phosphoinositide 3-kinase signaling to B-cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B-cell leukemia. Blood 2009;114:4703-12.
60. McElligott AM, Maginn EN, Greene LM, McGuckin S, Hayat A, Browne PV, et al. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia. Cancer Res 2009;69: 8366-75.
61. Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010;115:2619-29.
62. Marchisio PC, Bergui L, Corbascio GC, Cremona O, D'Urso N, Schena M, et al. Vinculin, talin, and integrins are localized at specific adhesion sites of malignant B lymphocytes. Blood 1988;72:830-3.
63. Houlihan JM, Biro PA, Harper HJ, Jenkinson HJ, Holmes CH. The human amnion is a site of MHC class Ib expression: evidence for the expression of HLA-E and HLA-G. J Immunol 1995;154:5665-74.
64. McMaster MT, Librach CL, Zhou Y, Lim KH, Janatpour MJ, DeMars R, et al. Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol 1995;154:3771-8.
65. Mallet V, Blaschitz A, Crisa L, Schmitt C, Fournel S, King A, et al. HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83+ dendritic cells expresses HLA-G as a membrane-bound and soluble protein. Int Immunol 1999;11:889-98. (Pubitemid 29276600)
66. Le Discorde M, Moreau P, Sabatier P, Legeais JM, Carosella ED. Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol 2003;64: 1039-44. (Pubitemid 37413712)
67. Menier C, Rabreau M, Challier JC, Le Discorde M, Carosella ED, Rouas-Freiss N. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. Blood 2004;104:3153-60. (Pubitemid 39507129)
68. Cirulli V, Zalatan J, McMaster M, Prinsen R, Salomon DR, Ricordi C, et al. The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes 2006;55:1214-22. (Pubitemid 44195357)
69. Naji A, Le Rond S, Durrbach A, Krawice-Radanne I, Creput C, Daouya M, et al. CD3 + CD4low and CD3 + CD8loware induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood 2007;110: 3936-48. (Pubitemid 350248449)
70. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N. HLA-G: from biology to clinical benefits. Trends Immunol 2008;29:125-32.
71. Caumartin J, Favier B, Daouya M, Guillard C, Moreau P, Carosella ED, et al. Trogocytosis-based generation of suppressive NK cells. EMBO J 2007;26:1423-33. (Pubitemid 46398697)
72. LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 2007;109:2040-8. (Pubitemid 46348204)
73. Flajollet S, Poras I, Carosella ED, Moreau P. RREB-1 is a transcriptional repressor of HLA-G. J Immunol 2009;183:6948-59.
74. Yu Z, Sun B, Kantarjian HM, Keating MH, Amin HM, Sun X. Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators. Leuk Lymphoma 2008;49:751-6. (Pubitemid 351517221)
75. Giannopoulos K, Dmoszynska A, Bojarska-Junak A, Schmitt M, Rolinski J. Expression of HLA-G in patients with B-cell chronic lymphocytic leukemia (B-CLL). Folia Histochem Cytobiol 2008;46:457-60.
76. Giannopoulos K, Schmitt M, Kowal M, Wlasiuk P, Bojarska-Junak A, Chen J, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008;20:677-82.
77. Erikci AA, Karagoz B, Ozyurt M, Ozturk A, Kilic S, Bilgi O. HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? Hematology 2009;14: 101-5.
78. Polakova K, Zeleznikova T, Russ G. HLA-G5 in the blood of leukemia patients and healthy individuals. Leuk Res 2013;37:139-45.
79. Ljunggren HG, Karre K. Host resistance directed selectivity against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985;162:1745-59. (Pubitemid 16149673)
80. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.Nature 1986;319: 675-8. (Pubitemid 16119452)
81. Ljunggren HG, Karre K. Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression. Opposing influences of T cell and natural killer mediated resistance? J Immunogenet 1986;13: 141-51. (Pubitemid 17001674)
82. Guillaume N, Marolleau JP. Is immune escape via human leukocyte antigen expression clinically relevant in chronic lymphocytic leukemia? Focus on the controversies. Leuk Res 2013;37:473-7.
83. Hallek M. State-of-the-art treatment of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program 2009:440-9.
84. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98: 1326-31.
85. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19: 2165-70. (Pubitemid 32366970)
86. Stilgenbauer S, Bullinger L, Lichter P, Döhner H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V[H] gene mutation status in pathogenesis and clinical course. Leukemia 2002;16:993-1007. (Pubitemid 34618838)
87. Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278-81. (Pubitemid 38525651)
88. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. Phosphatidylinositol 3-kinase-λ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078-88.
89. de RooijMF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al. The clinically active BTK inhibitor PCR-32765 targets B-cell receptor- and cytokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012;119:2590-4.
90. Suljagic M, Longo PG, Bennardo S, Perlas E, Leone G, Laurenti L, et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eu-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010;116:4894-905.
91. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-7.
92. Scielzo C, Apollonio B, Scarfo L, Janus A,Muzio M, Ten Hacken E, et al. The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia 2011;25:1760-7.
93. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T cell immunological synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide. Blood 2012;120:1412-21.
94. Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005;115:1797-805. (Pubitemid 40979718)